Kilitch Drugs (India) Limited (KILITCH) — share transfer | 14 April 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Kilitch Drugs (India) Limited received a SEBI-mandated certificate from MUFG Intime India Private Limited, its share transfer agent, confirming dematerialisation of securities for the quarter ended March 31, 2026. The filing, submitted to BSE and NSE on April 14, 2026, includes confirmation of listed securities and updated ownership records. The Registrar and Transfer Agent verified and cancelled physical certificates after validation.

📄 View Original Announcement (PDF)

About Kilitch Drugs (India) Limited (KILITCH)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹599.24 Cr P/E: 13.7 ROE: 10.4% ROCE: 11.9%

View full KILITCH stock details →

📡 Get AI alerts when KILITCH files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track KILITCH — Free

📊 More KILITCH filings

See all KILITCH filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when KILITCH files new disclosures

Track KILITCH filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track KILITCH — Free

Free account · 2 AI queries/day